Macimorelin - Aeterna Zentaris

Drug Profile

Macimorelin - Aeterna Zentaris

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Strongbridge Biopharma
  • Class Amides; Carboxylic acids; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Cachexia

Most Recent Events

  • 31 Oct 2018 Novo Nordisk signs agreement with Stonebridge Biopharma to acquire rights to macimorelin (Macrilen™) in USA and Canada for diagnosis of Adult growth hormone deficiency
  • 09 Aug 2018 Macimorelin - Aeterna Zentaris is available for licensing in World as of 09 Aug 2018.
  • 23 Jul 2018 Launched for Somatotropin deficiency (Diagnosis, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top